Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 2Withdrawn 1

Sponsor Class

INDUSTRY 5OTHER 3

Study Type

Interventional 3

Sponsor

Cancer Type

Genitourinary 3Plasma cell 1

Conditions

Prostatic Neoplasms 3

Interventions

Docetaxel 229Radiotherapy 206Magnetic Resonance Spectroscopy 204Radiosurgery 176Gemcitabine 155pembrolizumab 151Nivolumab 147enzalutamide 140Prednisone 129Cisplatin 123Leuprolide 119Androgen Antagonists 117Abiraterone Acetate 114Sunitinib 106Specimen Handling 94Surveys and Questionnaires 91Goserelin 91bicalutamide 90Carboplatin 88Ipilimumab 82gallium 68 PSMA-11 80Blood Specimen Collection 78Everolimus 73apalutamide 72Radiation 71Standard of Care 68Biopsy 68acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 66Paclitaxel 64Cyclophosphamide 62

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
OTHER × tasquinimod × Genitourinary × Clear all
NCT02159950 2023-04-27

Sipuleucel-T With or Without Tasquinimod in Treating Patients With Metastatic Hormone-Resistant Prostate Cancer

Roswell Park Cancer Institute

Phase 2 Completed
2 enrolled 7 charts
Genitourinary

Prostatic Neoplasms

NCT01513733 2018-09-04

CATCH

Duke University

Phase 1 Completed
25 enrolled
Genitourinary

Prostatic Neoplasms

NCT02396368 2015-11-20

Radium-223

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Phase 1 Withdrawn
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡